ACC 2026: Sotatercept Shows Signal in CpcPH-HFpEF at Lower Dose

Why It Matters

CpcPH‑HFpEF represents a high‑risk, older population with no approved targeted therapies, so a drug that improves hemodynamics could reshape treatment standards and create a new market segment.

Key Takeaways

• Sotatercept lowered pulmonary vascular resistance in CpcPH‑HFpEF.
• 0.3 mg/kg dose showed better safety than 0.7 mg/kg.
• Trial enrolled 164 patients, median age 75, NYHA III.
• Biomarkers and walk distance trends favored low dose.
• Phase III will target hospitalizations and clinical worsening.

Pulse Analysis

Combined post‑ and precapillary pulmonary hypertension in HFpEF patients (CpcPH‑HFpEF) has emerged as a distinct clinical entity with a grim prognosis. Patients experience persistent dyspnea, frequent hospital admissions, and limited therapeutic options beyond diuretics and standard HFpEF drugs. The condition’s dual vascular and cardiac origins make it resistant to conventional vasodilators, prompting a search for disease‑modifying agents that can address both pulmonary and cardiac remodeling. Sotatercept, an activin‑signaling inhibitor, offers a mechanistic approach that could fill this therapeutic void.

The CADENCE trial enrolled 164 elderly participants, predominantly NYHA class III, and compared placebo with two sotatercept doses administered tri‑weekly for six months. Both dosing arms achieved statistically significant reductions in pulmonary vascular resistance, the primary hemodynamic endpoint. Notably, the 0.3 mg/kg cohort demonstrated consistent improvements in secondary measures—lowered mean pulmonary artery pressure, reduced NT‑proBNP, and modest gains in six‑minute walk distance—while maintaining a safety profile comparable to placebo. The higher 0.7 mg/kg dose, although effective, incurred more dose interruptions linked to hemoglobin elevations, suggesting a narrower therapeutic window.

If phase‑III trials confirm these signals, sotatercept could become the first approved targeted therapy for CpcPH‑HFpEF, unlocking a sizable, underserved market. Success will hinge on precise patient identification, reimbursement strategies focused on hospitalization reduction, and clear safety monitoring protocols for older, multimorbid patients. Moreover, a positive outcome would validate activin pathway modulation as a broader strategy across pulmonary vascular diseases, potentially spurring additional pipeline investments.